The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.65
Bid: 3.50
Ask: 3.80
Change: 0.25 (7.35%)
Spread: 0.30 (8.571%)
Open: 3.43
High: 3.65
Low: 3.43
Prev. Close: 3.40
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

30 Jan 2015 15:58

RNS Number : 6667D
Allergy Therapeutics PLC
30 January 2015
 



For filings with the FCA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

Allergy Therapeutics PLC

 

 

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

 

3. Full name of person(s) subject to the notification obligation: iii

SOUTHERN FOX INVESTMENTS LTD.

4. Full name of shareholder(s)

(if different from 3.): iv

CHASE NOMINEES LTD -CMBLJPPB

5. Date of the transaction and date on which the threshold is crossed or reached: v

23rd January, 2015

6. Date on which issuer notified:

30th January, 2015

7. Threshold(s) that is/are crossed or

reached: vi, vii

Over 27.21%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ord GBP 0.01

 

GB00B02LCQ05

108,512,784

108,512,784

111,589,283

111,589,283

 

27.21%

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/ConversionPeriod xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exerciseprice

Expirationdate xvii

Exercise/Conversionperiod xviii

Number of votingrights instrumentrefers to

% of voting rights xix, xx

 

Nominal

Delta

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 111,589,283

 27.21%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

 

Proxy Voting:

10. Name of the proxy holder:

 SOUTHERN FOX INVESTMENTS LTD

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

 

13. Additional information:

14. Contact name:

 George O' Carroll

15. Contact telephone number:

 +353-61-472019

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLURVVRVBAAOAR
Date   Source Headline
8th Jan 20214:36 pmRNSPrice Monitoring Extension
5th Jan 20217:00 amRNSInitiation of peanut allergy biomarker study
14th Dec 20203:58 pmRNSDirector/PDMR Shareholding
8th Dec 20202:42 pmRNSResult of Annual General Meeting
20th Nov 20201:51 pmRNSGrant of Awards under Long Term Incentive Plan
20th Nov 20207:00 amRNSDirector/PDMR Shareholding
10th Nov 20207:05 amRNSAnnual Report & Accounts and AGM Notification
26th Oct 20207:00 amRNSInitiation of Grass MATA MPL exploratory study
12th Oct 20207:00 amRNSHolding(s) in Company
9th Oct 20207:00 amRNSDirector Dealings and Issue of Equity
23rd Sep 20207:00 amRNSPreliminary Results
3rd Sep 20207:00 amRNSAGY secures VLP technology platform
20th Jul 20207:30 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Record sales and a COVID-19 wildcard
15th Jul 202011:05 amRNSSecond Price Monitoring Extn
15th Jul 202011:00 amRNSPrice Monitoring Extension
15th Jul 20207:00 amRNSTrading Update
9th Jul 20207:00 amRNSInvalidation of Birch MATA MPL phase III results
1st Jul 20205:15 pmRNSTotal Voting Rights
1st Jul 20205:14 pmRNSBLOCK LISTING SIX MONTHLY RETURN
24th Jun 20204:41 pmRNSSecond Price Monitoring Extn
24th Jun 20204:36 pmRNSPrice Monitoring Extension
24th Jun 20207:00 amRNSTrading Update
18th May 20202:05 pmRNSSecond Price Monitoring Extn
18th May 20202:00 pmRNSPrice Monitoring Extension
23rd Apr 20204:41 pmRNSSecond Price Monitoring Extn
23rd Apr 20204:36 pmRNSPrice Monitoring Extension
22nd Apr 202010:11 amRNSEAACI review of adjuvants and formulations
1st Apr 20201:09 pmRNSGrant and Vesting of Awards
9th Mar 20207:15 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Consistent first-half revenue growth
4th Mar 20207:00 amRNSHalf-year Report
29th Jan 202012:00 pmRNSData for peanut allergy vaccine published in JACI
16th Jan 202012:25 pmRNSTrading Update & Notice of Results - Replacement
16th Jan 20208:00 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Sales growth well above market average
16th Jan 20207:00 amRNSHalf Year Trading Update & Notice of Results
2nd Dec 20199:57 amRNSHoldings in Company
29th Nov 201910:34 amRNSHoldings in Company
26th Nov 20197:00 amRNSUpdate to Grass MATA MPL Ph III clinical programme
25th Nov 201912:13 pmRNSResult of Annual General Meeting
22nd Oct 20199:23 amRNSAnnual Report and Accounts
26th Sep 20197:30 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Continuing to gain market share
25th Sep 20197:00 amRNSPreliminary Results
11th Jul 20197:00 amRNSTrading update
1st Jul 20197:21 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Successful legal outcome removes uncertainty
1st Jul 20197:16 amEQSHardman & Co Research: Oxford BioMedica (OXB): Eying up long-term value
27th Jun 20197:00 amRNSSuccessful Litigation Settlement
27th Jun 20197:00 amRNSTrading Statement
19th Jun 20197:00 amRNSBoard Change
11th Jun 20197:00 amRNSHoldings in Company
21st May 20197:15 amEQSHardman & Co Research: Allergy Therapeutics (AGY): House dust mite vaccine - clinical progress
20th May 20197:00 amRNSPositive top line phase I results for Acarovac MPL

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.